Coronary disease & ACS

Impact of beta-blockers on quality of life in patients with myocardial infarction without heart failure: A prespecified substudy of the DANBLOCK trial

Eur Heart J Cardiovasc PharmacotherPublished prespecified substudy of the DANBLOCK trial

Authors' conclusion

Overall, a high HRQoL was observed among post-MI patients. Beta-blocker therapy did not affect HRQoL after MI in patients without heart failure.

Study context

Population
Patients with a recent (≤14 days) myocardial infarction (MI) and left ventricular ejection fraction (LVEF) >40%randomised, 2681 (99%) completed at least one EQ-5D-5L questionnaire
Participants
2,707 patients
Comparison
Beta-blocker therapy or no beta-blocker
Primary endpoint
Between-group differences in change from baseline in EQ-5D index score and EQ VAS score
Follow-up
12 months
Methodological detailsrandomised, open-label
  • Randomised
  • Open-label

Primary result

As reported in the abstract

beta-blocker vs no beta-blockerMean difference (95% CI)P value
EQ-5D index score
−0.001(−0.016 to 0.013)
P = 0.86
EQ VAS score
−1.35(−2.85 to 0.15)
P = 0.08

Further findings

Baseline EQ-5D and EQ VAS scores

Median EQ-5D score
0.95 (IQR: 0.87-1.00)
Median EQ VAS score
77 (IQR: 65-87)
Scores remained stable throughout follow-up

Prespecified subgroups (age, sex, type of MI, and LVEF)

Results were consistent in prespecified subgroups

Original publication

Impact of beta-blockers on quality of life in patients with myocardial infarction without heart failure: A prespecified substudy of the DANBLOCK trial. Eur Heart J Cardiovasc Pharmacother. Published 11 November 2026. doi:10.1093/ehjcvp/pvag096

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.